Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iadademstat + Paclitaxel in Relapsed/Refractory SCLC and NEC
NCT05420636Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iadademstat in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), sponsored by Fox Chase Cancer Center. Started Dec 2022; status: terminated.
02
Drugs
iadademstat
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05420636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420636.